Treatment and clinical research in myasthenia gravis: How far have we come?

Annals of the New York Academy of Sciences

Volumn 1132, Issue , 2008, Pages 225-232

  Barohn, Richard J ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Azathioprine; Cyclosporine; Intravenous immunoglobulin; Myasthenia gravis; Mycophenolate mofetil; Plasmapheresis; Prednisone; Pyridostigmine; Thymectomy

Indexed keywords

AZATHIOPRINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHYSOSTIGMINE;

ARTIFICIAL VENTILATION; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CONFERENCE PAPER; MORTALITY; MYASTHENIA GRAVIS; PLASMAPHERESIS; THYMECTOMY;

EID: 45249125174     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1405.036     Document Type: Conference Paper

References (52)

1. Walker, M.B. 1934. Treatment of myasthenia gravis with physostigmine. Lancet 1 : 1200 1201.
2. Schumacher, C.H. & P. Roth. 1913. Thymektomie bei einem Fall von Murbus Basedowi mit Myasthenia. Mitteilungen Grensgebeiten Medizin Chirurgie 25 : 746 765.
3. Gronseth, G.S. & R.J. Barohn. 2000. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55 : 7 15.
4. Westerberg, M.R., K.R. Magee & F.E. Shiderman. 1951. Effect of 3-hydroxy phenyldimethylethyl ammonium chloride (Tensilon) in myasthenia gravis. Med. Bull. (Ann Arbor) 17 : 311 316.
5. Schwab, R.S. & W.H. Timberlake. 1954. Pyridostigmin (Mestinon) in the treatment of myasthenia gravis. N. Engl. J. Med. 251 : 271 272.
6. Tether, J.E. 1954. Mestinon in myasthenia gravis (preliminary report). Dis. Nerv. Syst. 15 : 227 231.
7. Palace, J., J. Newsom-Davis & B. Lecky. 1998. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50 : 1778 1783.
8. Tindall, R.S.A., J.A. Rollins, J.T. Phillips, et al. 1987. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 316 : 719 724.
9. Tindall, R.S.A., J.T. Phillips, J.A. Rollins, et al. 1993. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. N.Y. Acad. Sci. 681 : 539 551.
10. Cos, L., A.K. Mankodi, R. Tawil & C.A. Thornton. 2000. Mycophenolate mofetil (MyM) is safe and well-tolerated in myasthenia gravis (MG) [abstract]. Neurology 54 : A137.
11. Chaudhry, V., D.R. Cornblath, J.W. Griffin, et al. 2001. Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases. Neurology 56 : 94 96.
12. Ciafaloni, E., J.M. Massey, B. Tucker-Lipscomb & D.B. Sanders. 2001. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56 : 97 99.
13. Meriggioli, M.N., E. Ciafaloni, K.A. Al-Hayk, et al. 2003. Mycophenolate mofetil for myasthenia gravis: An analysis of efficacy, safety, and tolerability. Neurology 61 : 1438 1440.
14. Meriggioli, M.N., J. Rowin, J.G. Richman & S. Leurgans. 2003. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann. N.Y. Acad. Sci. 998 : 494 499.
15. Fateh-Moghadam, A., M. Wick, U. Besinger & R.G. Geursen. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1 : 848 849.
16. Arsura, E. 1989. Experience with intravenous immunoglobulin in myasthenia gravis. Clin. Immunol. Immunopathol. 53 : S170 S179.
17. Cosi, V., M. Lombardi, G. Piccolo & A. Erbetta. 1991. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol. Scand. 84 : 81 84.
18. Gajdos, P., S. Chevret, B. Clair, et al. 1997. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Ann. Neurol. 41 : 789 796.
19. Wolfe, G.I., R.J. Barohn, B.M. Foster, et al. 2002. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 26 : 549 552.
20. Antozzi, C., F. Baggi, A. Rigamonti, et al. 2008. Complete remission and autoantibody patterns in MG: a large population study [Abstract]. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
21. Mount, F.W. 1964. Corticotropin in treatment of ocular myasthenia. Arch. Neurol. 11 : 114 124.
22. Howard, F.M., D.D. Duane, E.H. Lambert & J.R. Daube. 1976. Alternate-date prednisone: preliminary report of a double-blind controlled study. Ann. N.Y. Acad. Sci. 274 : 596 607.
23. Lindberg, C., O. Anderson & A.K. Lefvert. 1998. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol. Scand. 97 : 370 373.
24. Gajdos, P., C. Tranchant, B. Clair, et al. 2005. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin. Arch. Neurol. 62 : 1689 1693.
25. Nagane, Y., K. Utsugisawa, D. Obara, et al. 2005. Efficacy of low-dose FK506 in the treatment of myasthenia gravis - a randomized pilot study. Eur. Neurol. 53 : 146 150.
26. Sanders, D., M. McDermott, C. Thornton, et al. 2007. A trial of mycophenolate mofetil (MMF) with prednisone as initial immunotherapy in myasthenia gravis (MG) (abstract). Neurology 62 (Suppl 1 107.
27. Zinman, L., E. Ng & V. Bril. 2007. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68 : 837 841.
28. Sanders, D.B. & Z.A. Siddiqi. 2008. Lessons from two trials of mycophenolate mofetil in myasthenia gravis. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
29. The Muscle Study Group. 2008. A trial of mycophenolate mofetil as initial immunotherapy in myasthenia gravis. Neurology. In Press.
30. Zinman, L. 2008. Intravenous immunoglobulin treatment for myasthenia gravis: effectiveness, limitations and novel therapeutic strategies. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In press.
31. Besinger, U.A., K.V. Toyka, K. Heininger, et al. 1981. Long-term correlation of clinical course and acetylcholine receptor antibody in patients with myasthenia gravis. Ann. N.Y. Acad. Sci. 377 : 812 815.
32. Besinger, U.S., K.V. Toyka, M. Homberg, et al. 1983. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology 33 : 1316 1321.
33. Barohn, R.J., D. McIntire, L. Herbelin, et al. 1998. Reliability testing of the quantitative myasthenia gravis score. Ann. N.Y. Acad. Sci. 841 : 769 772.
34. Wolfe, G.I., H.J. Kaminski, A. Jaretzki III., et al. 2003. Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy. Ann. N.Y. Acad. Sci. 998 : 473 480.
35. Jaretzki, III., A., R.J. Barohn, R.M. Ernstoff, et al. 2000. Myasthenia gravis: Recommendations for clinical research standards. Neurology 55 : 16 23.
36. Sanders, D.B., B. Tucker-Lipscomb & J.M. Massey. 2003. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Ann. N.Y. Acad. Sci. 998 : 440 444.
37. Rowin, J., M.N. Meriggioli, E. Tüzün, et al. 2004. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology 63 : 2390 2392.
38. Bedlack, R.S., D.L. Simel, H. Bosworth, et al. 2005. Quantitative myasthenia gravis score: Assessment of responsiveness and longitudinal validity. Neurology 64 : 1968 1970.
39. Gajdos, P., N. Simon, P. de Rohan Chabot & M. Goulon. 1983. Effets a long terme des echanges plasmatiques au cours de la myasthenia. Resultats d'une etude randomisee. Presse Med. 12 : 939 942.
40. Gajdos, P.H., H. Outin, D. Elkharrat, et al. 1984. High-dose intravenous gammaglobulin for myasthenia gravis. Lancet 1 : 406 407.
41. Gajdos, P., T. Sharshar & S. Chevret. 2003. Standards of measurement in myasthenia gravis. Ann. N.Y. Acad. Sci. 998 : 445 452.
42. Wolfe, G.I., L. Herbelin, S.P. Nations, et al. 1999. Myasthenia gravis activities of daily living profile. Neurology 52 : 1487 1489.
43. Herbelin, L.L., S.P. Nations, G.I. Wolfe, et al. 2001. The correlation between static fatigue testing and the quantitative myasthenia gravis score and activities of daily living profile. Neurology 56 : A63.
44. Pasnoor, M., L. Herbelin, D. Saperstein, et al. 2008. Correlation of outcome measures and static fatigue testing from a controlled study of mycophenolate mofetil in generalized MG [Abstract]. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
45. Ponsetti, J.M., J. Gamez, M. Lopez-Cano & M. Armengol. 2008. Tacrolimus for myasthenia gravis: a clinical study of 212 patients. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
46. Rowin, J. 2008. Etanercept in myasthenia gravis. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
47. Melms, A., R. Gold, J. Kummerle-Deschner, et al. 2008. Clinical response to rituximab and long-term follow-up in treatment-refractory MG [Abstract]. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
48. Hain, B., K. Jordan K, M. Deschauer & S. Zierz. 2006. Successful treatment of MuSK antibody-positive myasthenia ravis with rituximab. Muscle Nerve 33 : 575 580.
49. Wylam, M.E., P.M. Anderson, N.L. Kuntz & V. Rodriguez. 2003. Successful treatment of refractory myasthenia gravis using rituximab: A pediatric case report. J. Pediatr. 143 : 674 677.
50. Sussman, J.D. et al. 2008. Antisense treatment for myasthenia gravis: experience with Monarsen. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.
51. Drachman, D.B., R.J. Jones & R.A. Brodsky. 2003. Treatment of refractory myasthenia: "Rebooting" with high-dose cyclophosphamide. Ann. Neurol. 53 : 29 34.
52. Drachman, D.B., R.N. Adams, R. Hu, et al. 2008. Rebooting the immune system with high dose cyclophosphamide for treatment of refractory myasthenia gravis. Ann. N.Y. Acad. Sci. Myasthenia Gravis and Related Disorders: 11th International Conference. In Press.